{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:55:41Z","timestamp":1785200141213,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Science and Technology Innovation Fund of Jinshan District of Shanghai","award":["2018-3-04"],"award-info":[{"award-number":["2018-3-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s13577-020-00455-2","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T06:04:48Z","timestamp":1605506688000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["MiR-520a-3p inhibits malignant progression of epithelial ovarian cancer by targeting SUV39H1 expression"],"prefix":"10.1007","volume":"34","author":[{"given":"Jingwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"455_CR1","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.ctrv.2020.102021","volume":"86","author":"TT Huang","year":"2020","unstructured":"Huang TT, Lampert EJ, Coots C, et al. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021.","journal-title":"Cancer Treat Rev"},{"key":"455_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clinicians. 2007;57:43\u201366.","journal-title":"CA Cancer J Clinicians"},{"key":"455_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/cells9030719","volume":"9","author":"N Ahmed","year":"2020","unstructured":"Ahmed N, Kadife E, Raza A, et al. Ovarian cancer, cancer stem cells and current treatment strategies: a potential role of magmas in the current treatment methods. Cells. 2020;9:719.","journal-title":"Cells"},{"key":"455_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clinicians. 2018;68:284\u201396.","journal-title":"CA Cancer J Clinicians"},{"key":"455_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237\u201349.","journal-title":"Virchows Arch"},{"key":"455_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","volume":"2","author":"S Kim","year":"2018","unstructured":"Kim S, Han Y, Kim SI, et al. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol. 2018;2:20.","journal-title":"NPJ Precis Oncol"},{"key":"455_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield K, Ackland ML, Ahmed N, et al. Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol. 2009;113:143\u20138.","journal-title":"Gynecol Oncol"},{"key":"455_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.biopha.2017.10.019","volume":"96","author":"H Li","year":"2017","unstructured":"Li H, Zhu X, Zhang J, et al. MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN\/AKT pathway. Biomed Pharmacother. 2017;96:471\u20139.","journal-title":"Biomed Pharmacother"},{"key":"455_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1152\/physiolgenomics.00034.2008","volume":"33","author":"C Zhang","year":"2008","unstructured":"Zhang C. MicroRNomics: a newly emerging approach for disease biology. Physiol Genomics. 2008;33:139\u201347.","journal-title":"Physiol Genomics"},{"key":"455_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature02871","volume":"431","author":"V Ambros","year":"2004","unstructured":"Ambros V. The functions of animal microRNAs. Nature. 2004;431:350\u20135.","journal-title":"Nature"},{"key":"455_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-62703-748-8_2","volume":"1107","author":"KU Tufekci","year":"2014","unstructured":"Tufekci KU, Meuwissen RL, Genc S. The role of microRNAs in biological processes. Methods Mol Biol. 2014;1107:15\u201331.","journal-title":"Methods Mol Biol"},{"key":"455_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jb\/mvz079","volume":"167","author":"J Chen","year":"2020","unstructured":"Chen J, Jiang Q, Jiang XQ, et al. miR-146a promoted breast cancer proliferation and invasion by regulating NM23-H1. J Biochem. 2020;167:41\u20138.","journal-title":"J Biochem"},{"key":"455_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40659-020-00278-3","volume":"53","author":"G Zhao","year":"2020","unstructured":"Zhao G, Wei Z, Guo Y. MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma. Biol Res. 2020;53:11.","journal-title":"Biol Res"},{"key":"455_CR14","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/15384101.2019.1618121","volume":"18","author":"H Gao","year":"2019","unstructured":"Gao H, Li X, Zhan G, et al. Long noncoding RNA MAGI1-IT1 promoted invasion and metastasis of epithelial ovarian cancer via the miR-200a\/ZEB axis. Cell Cycle. 2019;18:1393\u2013406.","journal-title":"Cell Cycle"},{"key":"455_CR15","first-page":"2366","volume":"23","author":"YB Gong","year":"2019","unstructured":"Gong YB, Fan XH. MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1. Eur Rev Med Pharmacol Sci. 2019;23:2366\u201373.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"455_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen H, Yin X, et al. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res CR. 2019;38:81.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"455_CR17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41419-018-0946-6","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liu W, Shen F, et al. The activation of microRNA-520h-associated TGF-beta1\/c-Myb\/Smad7 axis promotes epithelial ovarian cancer progression. Cell Death Dis. 2018;9:884.","journal-title":"Cell Death Dis"},{"key":"455_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/1759-7714.13304","volume":"11","author":"L Yu","year":"2020","unstructured":"Yu L, Chen D, Song J. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p. Thorac Cancer. 2020;11:603\u201311.","journal-title":"Thorac Cancer"},{"key":"455_CR19","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.2147\/CMAR.S223473","volume":"11","author":"C Pan","year":"2019","unstructured":"Pan C, Liu Q, Wu X. HIF1alpha\/miR-520a-3p\/AKT1\/mTOR feedback promotes the proliferation and glycolysis of gastric cancer cells. Cancer Manag Res. 2019;11:10145\u201356.","journal-title":"Cancer Manag Res"},{"key":"455_CR20","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.prp.2018.09.012","volume":"214","author":"X Qu","year":"2018","unstructured":"Qu X, Yang L, Shi Q, et al. Lidocaine inhibits proliferation and induces apoptosis in colorectal cancer cells by upregulating mir-520a-3p and targeting EGFR. Pathol Res Pract. 2018;214:1974\u20139.","journal-title":"Pathol Res Pract"},{"key":"455_CR21","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1002\/jcp.27199","volume":"234","author":"CL Bi","year":"2019","unstructured":"Bi CL, Zhang YQ, Li B, et al. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK\/STAT signaling pathway. J Cell Physiol. 2019;234:4054\u201367.","journal-title":"J Cell Physiol"},{"key":"455_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.biopha.2018.07.119","volume":"107","author":"B Zhang","year":"2018","unstructured":"Zhang B, Yu L, Han N, et al. LINC01116 targets miR-520a-3p and affects IL6R to promote the proliferation and migration of osteosarcoma cells through the Jak-stat signaling pathway. Biomed Pharmacother. 2018;107:270\u201382.","journal-title":"Biomed Pharmacother"},{"key":"455_CR23","first-page":"146","volume":"9","author":"J Li","year":"2017","unstructured":"Li J, Wei J, Mei Z, et al. Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44. Am J Transl Res. 2017;9:146\u201354.","journal-title":"Am J Transl Res"},{"key":"455_CR24","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cancers11121917","volume":"11","author":"C Yang","year":"2019","unstructured":"Yang C, Kim HS, Park SJ, et al. Inhibition of miR-214\u20133p aids in preventing epithelial ovarian cancer malignancy by increasing the expression of LHX6. Cancers. 2019;11:1917.","journal-title":"Cancers"},{"key":"455_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2019.10.021","volume":"469","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang L, Wang B, et al. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Lett. 2020;469:54\u201367.","journal-title":"Cancer Lett"},{"key":"455_CR26","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/jcb.29387","volume":"121","author":"C Yang","year":"2020","unstructured":"Yang C, Li H, Zhang T, et al. miR-200c overexpression inhibits the invasion and tumorigenicity of epithelial ovarian cancer cells by suppressing lncRNA HOTAIR in mice. J Cell Biochem. 2020;121:1514\u201323.","journal-title":"J Cell Biochem"},{"key":"455_CR27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.biopha.2018.11.104","volume":"110","author":"J Li","year":"2019","unstructured":"Li J, Shao W, Feng H. MiR-542\u20133p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer. Biomed Pharmacother. 2019;110:850\u20136.","journal-title":"Biomed Pharmacother"},{"key":"455_CR28","first-page":"2321","volume":"22","author":"X Lv","year":"2018","unstructured":"Lv X, Li CY, Han P, et al. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K\/AKT\/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22:2321\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"455_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0092-8674(01)00542-6","volume":"107","author":"AH Peters","year":"2001","unstructured":"Peters AH, O\u2019Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107:323\u201337.","journal-title":"Cell"},{"key":"455_CR30","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/oncsis.2017.28","volume":"6","author":"T Yu","year":"2017","unstructured":"Yu T, Wang C, Yang J, et al. Metformin inhibits SUV39H1-mediated migration of prostate cancer cells. Oncogenesis. 2017;6:e324.","journal-title":"Oncogenesis"},{"key":"455_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/hep.26083","volume":"57","author":"DN Fan","year":"2013","unstructured":"Fan DN, Tsang FH, Tam AH, et al. Histone lysine methyltransferase, suppressor of variegation 3\u20139 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology. 2013;57:637\u201347.","journal-title":"Hepatology"},{"key":"455_CR32","doi-asserted-by":"publisher","first-page":"180118","DOI":"10.1098\/rsob.180118","volume":"8","author":"H Liu","year":"2018","unstructured":"Liu H, Ma Y, Liu C, et al. Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression. Open Biol. 2018;8:180118.","journal-title":"Open Biol"},{"key":"455_CR33","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1111\/jcmm.13716","volume":"22","author":"M Cai","year":"2018","unstructured":"Cai M, Chen Q, Shen J, et al. Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer. J Cell Mol Med. 2018;22:4721\u201331.","journal-title":"J Cell Mol Med"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13577-020-00455-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:02:48Z","timestamp":1614016968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13577-020-00455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s13577-020-00455-2","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"15 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors confirm that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were performed in accordance with the institutional guidelines from the Care and Use of Laboratory Animals of Jinshan Hospital affiliated to Fudan University and were approved by the Institutional Animal Ethics Committee (2018-30-02).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}